Dyskinesias
15 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Nervous System Diseases
Narrower: Chorea 8, Dystonia 2, Huntington Disease 7, Psychomotor Agitation 1, Tics 1, Tremor 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AB-1001 Gene Therapy for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active, self-directed electrical stimulation of the median nerve for tics | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive deep brain stimulation + conventional deep brain stimulation for dyskinesias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| apomorphine infusion for dyskinesias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baclofen for psychomotor agitation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for dystonia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-striatal rAAV5-miHTT for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lifus for dystonia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium sulphate prolonged-release 660 mg for tremor | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moderate doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + SRP-1005 for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tominersen for chorea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tominersen for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Votoplam (blinded) for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.